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Insect cells & baculovirus expression vector system (BEVS) is an efficient platform for the production of 
baculovirus vectors and the expression of recombinant proteins or VLPs (Virus Like Particles). This technology 
is increasingly used in large-scale manufacturing of human and veterinary vaccines. The production of safe and 
cost-effective vaccines requires the development of animal origin free and low-cost culture media supporting 
strong insect cell growth, high yield of baculovirus and sustained expression of recombinant proteins or VLPs. 
In this context, Boehringer-Ingelheim decided to develop its own animal origin free media (with similar or better 
performance than the commercial one) in collaboration with NRC and suppliers. The different steps, feedback 
and results will be presented in this poster.  
 
